Menu
Annual · values202520242023202220212020
Operating Cash Flow-20.45 M USD-24.67 M USD-32.02 M USD-39.03 M USD-30.26 M USD-17.70 M USD
Depreciation & Amortization122000 USD551000 USD571000 USD614000 USD685000 USD209000 USD
Stock-Based Compensation1.27 M USD3.13 M USD4.45 M USD5.81 M USD5.66 M USD1.49 M USD
Capital Expenditures16000 USD146000 USD180000 USD321000 USD2.03 M USD1.21 M USD
Cash Flow from Investing19.77 M USD22.44 M USD38.41 M USD49.95 M USD-143.12 M USD-1.40 M USD
Cash Flow from Financing-645000 USD-787000 USD-11.17 M USD-287000 USD163.94 M USD35.45 M USD
Dividends Paid
Stock Buybacks10.38 M USD
Free Cash Flow-20.47 M USD-24.82 M USD-32.20 M USD-39.35 M USD-32.28 M USD-18.91 M USD

Sensei Biotherapeutics Inc is a cutting-edge biotechnology company focused on developing novel immunotherapies to treat cancer. Primarily, the company aims to harness the power of the immune system to target and eliminate cancerous cells, leveraging breakthroughs in scientific research and molecular biology. Sensei Biotherapeutics operates in the burgeoning field of oncology, which remains a critical area of medical research due to the global impact of cancer. The company's proprietary platform technology is designed to generate highly specific and potent therapeutic agents that could potentially improve patient outcomes in various cancer types. By innovating within the field of cancer immunotherapy, Sensei Biotherapeutics serves a significant role in the pharmaceutical and biotechnology sectors, contributing to the development of next-generation treatment modalities. The company’s R&D efforts are instrumental in advancing therapeutic strategies that are shaping the future of personalized cancer care and increasing the potential for successful interventions across diverse patient populations.